GlassScriptPhysician profile
Farnaz Tabatabaian
NPI 1265752919
$75,676.48
in general payments reported to CMS, 2019-2025
14 companies · $7,360 in 2025
The $7,360 reported for 2025 was more than what 86% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $2,313 · 2021: $4,413 · 2022: $16K · 2023: $13K · 2024: $32K · 2025: $7,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Honoraria: $10K · Travel and Lodging: $4,102 · Food and Beverage: $3,821 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,367.30 |
| Honoraria | $10,366.42 |
| Travel and Lodging | $4,101.73 |
| Food and Beverage | $3,820.69 |
| Education | $398.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $38,849.38 | 2020-2025 | |
| Alk-Abello, INC | $14,425.77 | 2019-2023 | Ragwitek, Grastek, Odactra |
| Blueprint Medicines Corporation | $11,119.01 | 2023-2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $8,002.84 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,507.27 | 2020-2025 | Cuvitru |
| Astrazeneca Pharmaceuticals LP | $954.15 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $302.00 | 2019-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $201.48 | 2021-2023 | |
| Genentech USA, INC. | $149.99 | 2019 | |
| Grifols USA, LLC | $49.77 | 2022-2025 | Xembify |
| Glaxosmithkline, LLC. | $41.13 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $25.14 | 2022 | |
| Ionis Pharmaceuticals, INC. | $25.00 | 2025 | |
| Adma Biomanufacturing LLC | $23.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farnaz Tabatabaian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.